



[cancer.org](http://cancer.org) | 1.800.227.2345

## The History of Cancer

The study of cancer, called *oncology*, is the work of countless doctors and scientists around the world whose discoveries in anatomy, physiology, chemistry, epidemiology, and other related fields made oncology what it is today. Technological advances and the ever-increasing understanding of cancer make this field one of the most rapidly evolving areas of modern medicine.

The growth in our knowledge of cancer biology has led to remarkable progress in cancer prevention, early detection, and treatment. Scientists have learned more about cancer in the last 2 decades than had been learned in all the centuries preceding. This doesn't change the fact, however, that all scientific knowledge is based on the knowledge already acquired by the hard work and discovery of our predecessors – and we know that there's still a lot more to learn

- [Understanding What Cancer Is: Ancient Times to Present](#)
- [Understanding Cancer Causes: Ancient Times to Present](#)
- [History of Cancer Epidemiology: 18th Century to Present](#)
- [History of Cancer Screening and Early Detection: 20th Century to Present](#)
- [History of Cancer Treatments: Surgery](#)
- [History of Cancer Treatments: Hormone therapy](#)
- [History of Cancer Treatments: Radiation Therapy](#)
- [History of Cancer Treatments: Chemotherapy](#)
- [History of Cancer Treatments: Immunotherapy](#)
- [History of Cancer Treatments: Targeted Therapy](#)
- [Advancement of Cancer Survivorship](#)

---

# Understanding What Cancer Is: Ancient Times to Present

---

During the Renaissance, beginning in the 15th century, scientists developed greater understanding of the human body. Scientists like Galileo and Newton began to use the scientific method, which later was used to study disease. Autopsies, done by Harvey (1628), led to an understanding of the circulation of blood through the heart and body that had until then been a mystery.

In 1761, Giovanni Morgagni of Padua was the first to do something which has become routine today – he did autopsies to relate the patient’s illness to pathologic findings after death. This laid the foundation for scientific oncology, the study of cancer.

Contran R, Kumar V, Robbins S. *Robbins Pathologic Basis of Disease*, 4th ed. Philadelphia, Pa: WB Saunders; 1989.

Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. *N Engl J Med*. 2012;366(23):2207-2214.

Diamandopoulus GT. Cancer: An historical perspective. *Anticancer Res*. 1996;16:1595-1602.

Gallucci BB. Selected concepts of cancer as a disease: From the Greeks to 1900. *Oncol Nurs Forum*. 1985;12:67-71.

Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 1. *Cancer*. 2011;117(5):1097-1102.

Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 2. *Cancer*. 2011;117(12):2811-2820.

Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 3. *Cancer*. 2012;118(4):1155-1168.

Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. *Cancer*. 2012;118(20):4914-4928.

Institut Jules Bordet. The History of Cancer. Accessed at [www.bordet.be/en/presentation/history/cancer\\_e/cancer1.htm](http://www.bordet.be/en/presentation/history/cancer_e/cancer1.htm) on June 8, 2012.

Kardinal C, Yarbro J. A conceptual history of cancer. *Semin Oncol*. 1979;6:396-408.

Last Revised: January 4, 2018

---

## Understanding Cancer Causes: Ancient Times to Present

- [Early theories about cancer causes](#)
- [Development of modern knowledge about cancer causes](#)



not through some unidentified fluid.

### **Trauma theory**

Despite advances in the understanding of cancer, from the late 1800s until the 1920s, trauma was thought by some to cause cancer. This belief was maintained despite the failure of injury to cause cancer in experimental animals.

### **Infectious disease theory**

Zacutus Lusitani (1575-1642) and Nicholas Tulp (1593-1674), 2 doctors in Holland, concluded at almost the same time that cancer was contagious. They made this conclusion based on their experiences with breast cancer in members of the same household. Lusitani and Tulp publicized the contagion theory in 1649 and 1652, respectively. They proposed that cancer patients should be isolated, preferably outside



specific gene.

Scientists discovered that sometimes defective genes are inherited, and sometimes these inherited genes are defective at the points where certain chemicals also tend to cause damage. In other words, most of the things that caused cancer (carcinogens) caused genetic damage (mutations) that looked a lot like the mutations that could be inherited and could result in the same types of cancer if more mutations were introduced.

No matter which way the first mutation started (inborn or spontaneous), the cells that grew from the mutated cells led to groups of abnormal cells (called clones, or duplicates of the abnormal cell). The mutant clones evolved to even more malignant clones over time, and the cancer progressed by more and more genetic damage and mutations. The big difference between normal tissues and cancer is that normal cells with damaged DNA die, while cancer cells with damaged DNA do not. The discovery of this critical difference answered many questions that had troubled scientists for many years.

### **Oncogenes and tumor suppressor genes**

During the 1970s, scientists discovered 2 particularly important families of genes related to cancer: [oncogenes and tumor suppressor genes](#)<sup>19</sup>.

**Oncogenes:** These genes cause cells to grow out of control and become cancer cells. They are formed by changes or mutations of certain normal genes of the cell called *proto-oncogenes*. Proto-oncogenes are the genes that normally control how often a cell divides and the degree to which it *differentiates* (or specializes in a specific function in the body).

**Tumor suppressor genes:** These are normal genes that slow down cell division, repair DNA errors, and tell cells when to die (a process known as *apoptosis* or *programmed cell death*). When tumor suppressor genes don't work properly, cells can grow out of control, which can lead to cancer.

It may be helpful to think of a cell as a car. For it to work properly, there need to be ways to control how fast it goes. A proto-oncogene normally functions in a way that is similar to a gas pedal – it helps the cell grow and divide. An oncogene could be compared to a gas pedal that is stuck down, which causes the cell to divide out of control. A tumor suppressor gene is like the brake pedal on a car. It normally keeps the cell from dividing too quickly just as a brake keeps a car from going too fast. When something goes wrong with the gene, for example if a mutation causes it to stop working, cell division can get out of control.



Slowly, medical scientists are identifying the oncogenes and tumor suppressor genes that are damaged by chemicals or radiation and those that, when inherited, can lead to cancer. For example, the 1990s discovery of 2 genes that cause some breast cancers, BRCA1 and BRCA2, is a step forward because these genes can be used to identify people who have a higher risk of developing [breast cancer](#)<sup>20</sup>.

Other genes have been discovered that are linked to cancers that run in families, such as cancers of the [colon, rectum](#)<sup>21</sup>, [kidney](#)<sup>22</sup>, [ovary](#)<sup>23</sup>, [thyroid](#)<sup>24</sup>, [pancreas](#)<sup>25</sup>, and [skin melanoma](#)<sup>26</sup>. Familial cancer is not nearly as common as spontaneous cancer (cancer that is caused by DNA damage that starts during a person's lifetime). [Cancer linked to heredity](#)<sup>27</sup> is less than 15% of all cancers. Still, it's important to understand these cancers because with continued research in genetics we may be able to identify more people at very high risk.

Once researchers recognized the importance of specific genetic changes in cancer, they soon began working to develop [targeted therapies](#)<sup>28</sup> (drugs or substances that interfere with specific molecules) to overcome the effects of these changes in tumor suppressor genes and oncogenes.

## Hyperlinks

1. [www.cancer.org/cancer/risk-prevention/infections.html](http://www.cancer.org/cancer/risk-prevention/infections.html)

2. [able to identify genes that can help identify people at high risk of developing cancer](#) (more)Tj 0 g 1 0 0 1 72 5 m.htm29 72 5 m4

17. [www.cancer.org/cancer/types/penile-cancer.html](http://www.cancer.org/cancer/types/penile-cancer.html)
  18. [www.cancer.org/cancer/types/oral-cavity-and-oropharyngeal-cancer.html](http://www.cancer.org/cancer/types/oral-cavity-and-oropharyngeal-cancer.html)
  19. [www.cancer.org/cancer/understanding-cancer/genes-and-cancer.html](http://www.cancer.org/cancer/understanding-cancer/genes-and-cancer.html)
  20. [www.cancer.org/cancer/types/breast-cancer.html](http://www.cancer.org/cancer/types/breast-cancer.html)
  21. [www.cancer.org/cancer/types/colon-rectal-cancer.html](http://www.cancer.org/cancer/types/colon-rectal-cancer.html)
  22. [www.cancer.org/cancer/types/kidney-cancer.html](http://www.cancer.org/cancer/types/kidney-cancer.html)
  23. [www.cancer.org/cancer/types/ovarian-cancer.html](http://www.cancer.org/cancer/types/ovarian-cancer.html)
  24. [www.cancer.org/cancer/types/thyroid-cancer.html](http://www.cancer.org/cancer/types/thyroid-cancer.html)
  25. [www.cancer.org/cancer/types/pancreatic-cancer.html](http://www.cancer.org/cancer/types/pancreatic-cancer.html)
  26. [www.cancer.org/cancer/types/melanoma-skin-cancer.html](http://www.cancer.org/cancer/types/melanoma-skin-cancer.html)
-

---

# **History of Cancer Epidemiology: 18th Century to Present**

became popular in London, John Hill wrote a book entitled *Cautions Against the Immoderate Use of Snuff*. These first observations linking [tobacco and cancer](#)<sup>5</sup> led to epidemiologic research many years later (in the 1950s and early 1960s) which showed that smoking causes lung cancer and led to the US Surgeon General's 1964 report *Smoking and Health*.

Epidemiologists continue to search for factors that cause cancer (like tobacco use,

---

---

1602.

Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 3. *Cancer*. 2012;118(4):1155-1168.

Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. *Cancer*. 2012;118(20):4914-4928.

Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part 5. *Cancer*. 2013;119(8):1450-1466.

Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part 6. *Cancer*. 2013;119(23):4058-4082.

Institut Jules Bordet. The History of Cancer. Accessed at [www.bordet.be/en/presentation/history/cancer\\_e/cancer1.htm](http://www.bordet.be/en/presentation/history/cancer_e/cancer1.htm) on June 8, 2012.

Kardinal C, Yarbro J. A conceptual history of cancer. *Semin Oncol*. 1979;6:396-408.

Last Revised: June 12, 2014

---

## History of Cancer Screening and Early Detection: 20th Century to Present

- [The future of cancer screening and early detection](#)

Screening refers to tests used to find a disease, such as cancer, in people who do not have any symptoms.

The first screening test to be widely used for cancer was the Pap test. The test was developed by George Papanicolaou as a research method in understanding the menstrual cycle. Papanicolaou soon recognized its potential for finding cervical cancer early and presented his findings in 1923. At first, most doctors were skeptical, and it was not until the American Cancer Society (ACS) promoted the test during the early 1960s that this test became widely used. Since that time, cervical cancer incidence and mortality rates have decreased by more than 50% due to screening, which can detect

both cervical pre-cancers and cervical cancer at an early stage.

Modern mammography methods were developed late in the 1960s and first officially recommended by the ACS in 1976. The mammogram continues to be the most reliable way to screen for breast cancer.

Current [American Cancer Society guidelines](#)<sup>1</sup> include methods for early detection of cervical, breast, colorectal, lung, and prostate cancers.

## The future of cancer screening and early detection

### Expression profiling and proteomics

Expression profiling lets scientists determine relative output of hundreds or even thousands of molecules (including the proteins made by RNA, DNA, or even a cell or tissue) at one time. Knowing what proteins are present in cells can tell scientists a lot about how the cell is behaving. In cancer, it can help distinguish more aggressive cancers from less aggressive ones, and can often help predict which drugs the tumor is likely to respond to.

Proteomic methods are also being tested for cancer screening. For most types of cancer, measuring the amount of one protein in the blood is not very good at finding early cancers. But researchers are hopeful that comparing the relative amounts of many proteins may be more useful, and that finding large amounts of certain proteins and less of others can provide accurate, useful information about cancer treatment and its outcomes. Proteins (and other types of molecules) are even found in exhaled breath, which is now being tested to find out if it can show early signs of lung cancer. This is an exciting area of research and early results in lung and colorectal cancer studies have been promising.

### Nanotechnology

New technology for producing materials that form extremely tiny particles is leading to very promising imaging tests that can more accurately show the location of tumors. It also is aiding the development of new ways to deliver drugs more specifically and effectively to cancer cells.

## Hyperlinks

1. [www.cancer.org/cancer/screening/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html](http://www.cancer.org/cancer/screening/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html)

## References

American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO's Annual Report on Progress Against Cancer. Accessed at [www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2010.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2010.pdf) on June 8, 2012.

American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO's Annual Report on Progress Against Cancer. Accessed at [www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2011.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2011.pdf) on June 8, 2012.

American Society of Clinical Oncology. Progress & Timeline. Accessed at [www.cancerprogress.net/timeline/major-milestones-against-cancer](http://www.cancerprogress.net/timeline/major-milestones-against-cancer) on June 12, 2014.

Contran R, Kumar V, Robbins S. *Robbins Pathologic Basis of Disease*, 4th ed. Philadelphia, Pa: WB Saunders; 1989.

CureToday. Timeline: Milestones in Cancer Treatment. Accessed at [www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article\\_id/631](http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/631) on June 7, 2012.

Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. *N Engl J Med*. 2012;366(23):2207-2214.

Diamandopoulus GT. Cancer: An historical perspective. *Anticancer Res*. 1996;16:1595-1602.

Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part 5. *Cancer*. 2013;119(8):1450-1466.

Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part 6. *Cancer*. 2013;119(23):4058-4082.

Institut Jules Bordet. The History of Cancer. Accessed at [www.bordet.be/en/presentation/history/cancer\\_e/cancer1.htm](http://www.bordet.be/en/presentation/history/cancer_e/cancer1.htm) on June 8, 2012.

Kardinal C, Yarbro J. A conceptual history of cancer. *Semin Oncol.* 1979;6:396-408.

Last Revised: May 17, 2021

---

# History of Cancer Treatments: Surgery

- [The future of cancer surgery](#)



Three surgeons stand out because of their contributions to the art and science of cancer surgery: Bilioth in Germany, Handley in London, and Halsted in Baltimore. Their work led to “cancer operations” designed to remove the entire tumor along with the lymph nodes in the region where the tumor was located.

William Stewart Halsted, professor of surgery at Johns Hopkins University, developed the radical mastectomy during the last decade of the 19th century. His work was based in part on that of W. Sampson Handley, the London surgeon who believed that cancer spread outward by invasion from the original growth. (The general concept of the radical mastectomy can be traced all the way back to Lorenz Heister, a German who wrote about his ideas for mastectomy and lumpectomy in his book, *Chirurgie*, published in 1719.)

Halsted did not believe that cancers usually spread through the bloodstream: “Although it undoubtedly occurs, I am not sure that I have observed from [breast cancer](#)<sup>1</sup>, metastasis which seemed definitely to have been conveyed by way of the blood vessels.” He believed that adequate local removal of the cancer would cure it – if the cancer later appeared elsewhere, it was a new process. That belief led him to develop the radical mastectomy for breast cancer. This became the basis of cancer surgery for almost a century. Then, in the 1970s, modern [clinical trials](#)<sup>2</sup> demonstrated that less extensive surgery is equally effective for most women with breast cancer. Today, a radical mastectomy is almost never done and the “modified radical mastectomy” is performed less frequently than before. Most women with breast cancer now have the primary tumor removed (lumpectomy), and then have radiation therapy.

At the same time Halsted and Handley were developing their radical operations, another surgeon was asking, “What is it that decides which organs shall suffer in a case of disseminated cancer?” Stephen Paget, an English surgeon, concluded that cancer cells spread by way of the bloodstream to all organs in the body but were able to grow only in a few organs. In a brilliant leap of logic he drew an analogy between cancer metastasis and seeds that “are carried in all directions, but they can only live and grow if they fall on congenial soil.”

Paget’s conclusion that cells from a primary tumor spread through the bloodstream but could grow only in certain, and not all, organs was an accurate and highly sophisticated hypothesis that was confirmed by the techniques of modern cellular and molecular biology almost a hundred years later. This understanding of metastasis became a key element in recognizing the limitations of cancer surgery. It eventually allowed doctors to develop systemic treatments used after surgery to destroy cells that had spread throughout the body so that they could use less mutilating operations in treating many types of cancer. Today these systemic treatments may also be used before surgery.

During the final decades of the 20th century, surgeons developed greater technical expertise in minimizing the amounts of normal tissue removed during cancer operations. Like the trend from radical mastectomy to lumpectomy, progress was also made in removing bone and soft tissue tumors of the arms and legs without the need for amputation in most cases, and in avoiding a [colostomy](#)<sup>3</sup> for most patients with [rectal cancer](#)<sup>4</sup>. This progress depended not only on understanding cancer better as a disease and on better surgical instruments, but also on combining surgery with chemotherapy and/or radiation.

Until near the end of the 20th century, diagnosing cancer often required “exploratory surgery” to open the abdomen (belly) or chest so the surgeon could take tissue samples to be tested for cancer. Starting in the 1970s, progress in [imaging tests](#)<sup>5</sup> such as ultrasound (sonography), computed tomography (CT scans), magnetic resonance imaging (MRI scans), and positron emission tomography (PET scans) have replaced many exploratory operations. CT scans and ultrasound can also be used to guide biopsy needles into tumors.

Today, doctors use instruments with fiberoptic technology and miniature video cameras to look inside the body. Surgeons can operate using special surgical instruments through narrow tubes put into small cuts in the skin. These instruments can be used to look and work inside the abdomen (laparoscopic surgery) or chest (thoroscopic surgery). A similar instrument, the endoscope, can be used to remove some tumors in the [colon](#)<sup>6</sup>, [esophagus](#)<sup>7</sup>, or [bladder](#)<sup>8</sup> by entering through natural body openings such as the mouth or anus.

Less invasive ways of destroying tumors without removing them are being studied and/or used. Cryosurgery (also called cryotherapy or cryoablation) uses liquid nitrogen spray or a very cold probe to freeze and kill abnormal cells. Lasers can be used to cut through tissue (instead of using a scalpel) or to vaporize (burn and destroy) cancers of the [cervix](#)<sup>9</sup>, [larynx](#)<sup>10</sup> (voice box), [liver](#)<sup>11</sup>, [rectum](#)<sup>12</sup>, [skin](#)<sup>13</sup>, and other organs. Radiofrequency ablation transmits radio waves to a small antenna placed in the tumor to kill cancer cells by heating them.

## The future of cancer surgery

### Robotic surgery

This term refers to manipulation of surgical instruments remotely by robot arms and other devices controlled by a surgeon. Robotic systems have been used for several types of cancer surgery; radical prostatectomy is among the most common uses in surgical oncology. As mechanical and computer technology improve, some researchers

expect future systems will be able to remove tumors more completely and with less surgical trauma.

## Hyperlinks

1. [www.cancer.org/cancer/types/breast-cancer.html](http://www.cancer.org/cancer/types/breast-cancer.html)
2. [www.cancer.org/cancer/managing-cancer/making-treatment-decisions/clinical-trials.html](http://www.cancer.org/cancer/managing-cancer/making-treatment-decisions/clinical-trials.html)
3. [www.cancer.org/cancer/managing-cancer/treatment-types/surgery/ostomies/colostomy.html](http://www.cancer.org/cancer/managing-cancer/treatment-types/surgery/ostomies/colostomy.html)
4. [www.cancer.org/cancer/types/colon-rectal-cancer.html](http://www.cancer.org/cancer/types/colon-rectal-cancer.html)
5. [www.cancer.org/cancer/diagnosis-staging/tests/imaging-tests/imaging-radiology-tests-for-cancer.html](http://www.cancer.org/cancer/diagnosis-staging/tests/imaging-tests/imaging-radiology-tests-for-cancer.html)
6. [www.cancer.org/cancer/types/colon-rectal-cancer.html](http://www.cancer.org/cancer/types/colon-rectal-cancer.html)
7. [www.cancer.org/cancer/types/esophagus-cancer.html](http://www.cancer.org/cancer/types/esophagus-cancer.html)



# History of Cancer Treatments: Hormone therapy

Another 19th century discovery laid the groundwork for an important modern method to treat and prevent [breast cancer](#)<sup>1</sup>. Thomas Beatson graduated from the University of Edinburgh in 1874 and developed an interest in the relation of the ovaries to milk formation in the breasts. In 1878 he discovered that the breasts of rabbits stopped producing milk after he removed the ovaries. He described his results to the Edinburgh Medico-Chirurgical Society in 1896: “This fact seemed to me of great interest, for it pointed to one organ holding control over the secretion of another and separate organ.”

Because the breast was “held in control” by the ovaries, Beatson decided to test removal of the ovaries (called oophorectomy) in advanced breast cancer. He found that oophorectomy often resulted in improvement for breast cancer patients. He also suspected that “the ovaries may be the exciting cause of carcinoma” of the breast. He had discovered the stimulating effect of the female ovarian hormone (estrogen) on breast cancer, even before the hormone itself was discovered. His work provided a foundation for the modern use of hormone therapy, such as tamoxifen and the aromatase inhibitors, to treat or prevent breast cancer.

A half century after Beatson’s discovery, Charles Huggins, a urologist at the University of Chicago, reported dramatic regression of metastatic [breast cancer](#)<sup>1</sup>

American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention and Screening. Accessed at [www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA\\_2009.pdf](http://www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_2009.pdf) on June 8, 2012.

American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO's Annual Report on Progress Against Cancer. Accessed at [www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2010.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2010.pdf) on June 8, 2012.

American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO's Annual Report on Progress Against Cancer. Accessed at [www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2011.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2011.pdf) on June 8, 2012.

American Society of Clinical Oncology. Progress & Timeline. Accessed at [www.cancerprogress.net/timeline/major-milestones-against-cancer](http://www.cancerprogress.net/timeline/major-milestones-against-cancer) on June 12, 2014.

Contran R, Kumar V, Robbins S. *Robbins Pathologic Basis of Disease*, 4th ed. Philadelphia, Pa: WB Saunders; 1989.

CureToday. Timeline: Milestones in Cancer Treatment. Accessed at [www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article\\_id/631](http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/631) on June 7, 2012.

Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. *N Engl J Med*. 2012;366(23):2207-2214.

Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 3. *Cancer*. 2012;118(4):1155-1168.

Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. *Cancer*. 2012;118(20):4914-4928.

Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part 5. *Cancer*. 2013;119(8):1450-1466.

Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part 6. *Cancer*. 2013;119(23):4058-4082.

Last Revised: June 12, 2014

# History of Cancer Treatments: Radiation Therapy

In 1896 a German physics professor, Wilhelm Conrad Roentgen, presented a remarkable lecture entitled “Concerning a New Kind of Ray.” Roentgen called it the “X-ray”, with “x” being the algebraic symbol for an unknown quantity. There was immediate worldwide excitement. Within months, systems were being devised to use x-rays for diagnosis, and within 3 years radiation was used in to treat cancer.

In 1901 Roentgen received the first Nobel Prize awarded in physics. Radiation therapy began with radium and with relatively low-voltage diagnostic machines. In France, a major breakthrough took place when it was discovered that daily doses of radiation over several weeks greatly improved the patient’s chance for a cure. The methods and the machines that deliver radiation therapy have steadily improved since then.

At the beginning of the 20th century, shortly after radiation began to be used for diagnosis and therapy, it was discovered that [radiation could cause cancer](#)<sup>1</sup> as well as cure it. Many early radiologists used the skin of their arms to test the strength of radiation from their radiotherapy machines, looking for a dose that would produce a pink reaction (erythema) which looked like sunburn. They called this the “erythema dose,” and this was considered an estimate of the proper daily fraction of radiation. It’s no surprise that many of them developed leukemia from regularly exposing themselves to radiation.

Advances in radiation physics and computer technology during the last quarter of the 20th century made it possible to aim radiation more precisely. *Conformal radiation therapy (CRT)* uses CT images and special computers to very precisely map the location of a cancer in 3 dimensions. The patient is fitted with a plastic mold or cast to keep the body part still and in the sam7454c(curelocat8rogydfthem devlationcoulase or cast to)Tj 0 g 1

damage to nearby normal tissues.

*Stereotactic radiosurgery* and *stereotactic radiation therapy* are terms that describe several techniques used to deliver a large, precise radiation dose to a small tumor. The term *surgery* may be confusing because no cutting is actually done. The most common site treated with this radiation technique is the brain. A linear accelerator, or special machines such as the Gamma Knife or CyberKnife, can be used to deliver this treatment.

*Intraoperative radiation therapy* (IORT) is a form of treatment that delivers radiation at the time of surgery. The radiation can be given directly to the cancer or to the nearby tissues after the cancer has been removed. It's more commonly used in abdominal or pelvic cancers and in cancers that tend to recur (come back after treatment). IORT minimizes the amount of tissue that's exposed to radiation because normal tissues can be moved out of the way during surgery and shielded, allowing a higher dose of radiation to the cancer.

*Chemical modifiers* or *radiosensitizers* are substances that make cancer more sensitive to radiation. The goal of research into these types of substances is to develop agents that will make the tumor more sensitive without affecting normal tissues. Researchers are also looking for substances that may help protect normal cells from radiation.

## Hyperlinks

1. [www.cancer.org/cancer/risk-prevention/radiation-exposure.html](http://www.cancer.org/cancer/risk-prevention/radiation-exposure.html)

## References

American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research



[www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2011.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2011.pdf) on June 8, 2012.

American Society of Clinical Oncology. Progress & Timeline. Accessed at [www.cancerprogress.net/timeline/major-milestones-against-cancer](http://www.cancerprogress.net/timeline/major-milestones-against-cancer) on June 12, 2014.

CureToday. Timeline: Milestones in Cancer Treatment. Accessed at [www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article\\_id/631](http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/631) on June 7, 2012.

Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. *N Engl J Med*. 2012;366(23):2207-2214.

Hajdu SI. A Note From History: Landmarks in History of Cancer, Part 4. *Cancer*. 2012;118(20):4914-4928.

Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part 5. *Cancer*. 2013;119(8):1450-1466.

Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part 6. *Cancer*. 2013;119(23):4058-4082.

Last Revised: June 12, 2014

---

## History of Cancer Treatments: Chemotherapy

During World War II, naval personnel who were exposed to mustard gas during military action were found to have toxic changes in the bone marrow cells that develop into blood cells. During that same period, the US Army was studying a number of chemicals related to mustard gas to develop more effective agents for war and also develop protective measures. In the course of that work, a compound called *nitrogen mustard* was studied and found to work against a cancer of the lymph nodes called [lymphoma](#)<sup>1</sup>. This agent served as the model for a long series of similar but more effective agents (called *alkylating agents*) that killed rapidly growing cancer cells by damaging their DNA.

Not long after the discovery of nitrogen mustard, Sidney Farber of Boston demonstrated

that aminopterin, a compound related to the vitamin folic acid, produced remissions in [children with acute leukemia](#)<sup>2</sup>. Aminopterin blocked a critical chemical reaction needed for DNA replication. That drug was the predecessor of methotrexate, a cancer treatment drug used commonly today. Since then, other researchers discovered drugs that block different functions in cell growth and replication. The era of chemotherapy had begun.

Metastatic cancer was first cured in 1956 when methotrexate was used to treat a rare tumor called choriocarcinoma. Over the years, chemotherapy drugs (chemo) have successfully treated many people with cancer. Long-term remissions and even cures of many patients with [Hodgkin disease](#)<sup>3</sup> and childhood ALL (acute lymphoblastic leukemia) treated with chemo were first reported during the 1960s. Cures of [testicular cancer](#)<sup>4</sup> were seen during the next decade. Many other cancers can be controlled with chemo for long periods of time, even if they are not cured. Today, several approaches are available to improve the activity and reduce the side effects of chemo. These include:

- New drugs, new combinations of drugs, and new delivery techniques
- Novel approaches that target drugs more specifically at the cancer cells (such as liposomal therapy and monoclonal antibody therapy) to produce fewer side effects
- Drugs to reduce side effects, like colony-stimulating factors, chemoprotective agents (such as dexrazoxane and amifostine), and anti-emetics (to reduce nausea and vomiting)
- Agents that overcome multi-drug resistance (when the cancer doesn't respond to the usual treatment drugs)

Early in the 20th century, only cancers small and localized enough to be completely removed by surgery were curable. Later, radiation was used after surgery to control small tumor growths that were not surgically removed. Finally, chemotherapy was added to destroy small tumor growths that had spread beyond the reach of the surgeon and radiotherapist. Chemo used after surgery to destroy any remaining cancer cells in the body is called *adjuvant therapy*. Adjuvant therapy was tested first in [breast cancer](#)<sup>5</sup> and found to be effective. It was later used in [colon cancer](#)<sup>6</sup>, testicular cancer, and others.

A major discovery was the advantage of using multiple chemotherapy drugs (known as combination chemotherapy) over single agents. Some types of very fast-growing [leukemia](#)<sup>7</sup> and lymphoma (tumors involving the cells of the bone marrow and lymph nodes, respectively) responded very well to combination chemo, and [clinical trials](#)<sup>8</sup> led to gradual improvement of the drug combinations used. Many of these tumors can be cured today by appropriate combination chemotherapy.

The approach to patient treatment has become more scientific with the introduction of

clinical trials on a wide basis throughout the world. Clinical trials compare new treatments to standard treatments and contribute to a better understanding of treatment benefits and risks. They are used to test theories about cancer learned in the basic science laboratory and also test ideas drawn from the clinical observations on cancer patients. They are necessary for continued progress.

## Hyperlinks

1. [www.cancer.org/cancer/types/lymphoma.html](http://www.cancer.org/cancer/types/lymphoma.html)

[www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article\\_id/631](http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/631) on June 7, 2012.

---

## **History of Cancer Treatments: Immunotherapy**

used to destroy cancer cells. Using technology that was first developed during the 1970s, scientists can mass-produce monoclonal antibodies that are specifically targeted to chemical components of cancer cells. Refinements to these methods, using recombinant DNA technology, have improved the effectiveness and decreased the side effects of these treatments. The first therapeutic monoclonal antibodies, rituximab (Rituxan) and trastuzumab (Herceptin) were approved during the late 1990s to treat [lymphoma](#)<sup>2</sup> and [breast cancer](#)<sup>3</sup>, respectively. Monoclonal antibodies now are routinely used to treat certain cancers, and many more are being studied.

Scientists are also studying vaccines that boost the body's immune response to cancer cells. In 2010, the FDA approved sipuleucel-T (Provenge), a cancer vaccine for metastatic hormone-refractory [prostate cancer](#)<sup>4</sup> (prostate cancer that has spread and is no longer responding to hormone treatment). Unlike a preventive vaccine, which is given to prevent disease, Provenge boosts the immune system's ability to attack cancer cells in the body. This treatment has been shown to help certain men with prostate cancer live longer, though it does not cure the disease. It represents an important step forward in cancer treatment.

## The future of immunotherapy

Drugs aimed at specific immune checkpoints are being developed to help the immune system better kill cancer cells.

## Hyperlinks

1. [www.cancer.org/cancer/managing-cancer/making-treatment-decisions/clinical-trials.html](http://www.cancer.org/cancer/managing-cancer/making-treatment-decisions/clinical-trials.html)
2. [www.cancer.org/cancer/types/lymphoma.html](http://www.cancer.org/cancer/types/lymphoma.html)
3. [www.cancer.org/cancer/types/breast-cancer.html](http://www.cancer.org/cancer/types/breast-cancer.html)
4. [www.cancer.org/cancer/types/prostate-cancer.html](http://www.cancer.org/cancer/types/prostate-cancer.html)

## References

American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention and Screening. Accessed at [www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA\\_2009.pdf](http://www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_2009.pdf) on June 8, 2012.

American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO's Annual

Report on Progress Against Cancer. Accessed at [www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2010.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2010.pdf) on June 8, 2012.

American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO's Annual Report on Progress Against Cancer. Accessed at [www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2011.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2011.pdf) on June 8, 2012.

American Society of Clinical Oncology. Progress & Timeline. Accessed at [www.cancerprogress.net/timeline/major-milestones-against-cancer](http://www.cancerprogress.net/timeline/major-milestones-against-cancer) on June 12, 2014.

CureToday. Timeline: Milestones in Cancer Treatment. Accessed at [www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article\\_id/631](http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/631) on June 7, 2012.

Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. *N Engl J Med*. 2012;366(23):2207-2214.

Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part 5. *Cancer*. 2013;119(8):1450-1466.

Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part 6. *Cancer*. 2013;119(23):4058-4082.

Last Revised: June 12, 2014

---

## History of Cancer Treatments: Targeted Therapy

- [Growth signal inhibitors](#)
- [Angiogenesis inhibitors](#)
- [Apoptosis-inducing drugs](#)
- [The future of targeted therapies](#)

Until the late 1990s nearly all drugs used in cancer treatment (with the exception of

hormone treatments) worked by killing cells that were in the process of replicating their DNA and dividing to form 2 new cells. These chemotherapy drugs also killed some normal cells but had a greater effect on cancer cells.

Targeted therapies work by influencing the processes that control growth, division, and spread of cancer cells, as well as the signals that cause cancer cells to die naturally (the way normal cells do when they are damaged or old). Targeted therapies work in several ways.

## **Growth signal inhibitors**

Growth factors are hormone-like substances that help tell cells when to grow and divide. Their role in fetal growth and repair of injured tissue was first recognized in the 1960s. Later it was realized that abnormal forms of growth factors or abnormally high levels of growth factors contribute to the growth and spread of cancer cells. Researchers have also started to understand how cells recognize and respond to these factors, and how that can lead to signals inside the cells that cause the abnormal features found in cancer cells. Changes in these signal pathways have also been identified as a cause of the abnormal behavior of cancer cells.

During the 1980s, scientists found that many of the growth factors and other substances responsible for recognizing and responding to growth factors are actually products of oncogenes. Among the earliest targeted therapies that block growth signals are trastuzumab (Herceptin), gefitinib (Iressa), imatinib (Gleevec), and cetuximab (Erbitux). Many others are available today.

## **Angiogenesis inhibitors**

Angiogenesis is the creation of new blood vessels. The term comes from 2 Greek words: *angio*, meaning “blood vessel,” and *genesis*, meaning “beginning.” Normally, this is a healthy process. New blood vessels, for instance, help the body heal wounds and repair damaged tissues. But in a person with cancer, this same process creates new, very small blood vessels that give a tumor its own blood supply and allow it to grow.

Anti-angiogenesis agents are types of targeted therapy that use drugs or other substances to stop tumors from making the new blood vessels they need to keep growing. This concept was first proposed by Judah Folkman in the early 1970s, but it wasn't until 2004 that the first angiogenesis inhibitor, bevacizumab (Avastin), was approved. Currently used to treat advanced [colorectal](#)<sup>1</sup>, [kidney](#)<sup>2</sup>, and [lung cancers](#)<sup>3</sup>, bevacizumab is being studied as treatment for many other types of cancer, too. And many new drugs that block angiogenesis have become available since 2004.

## Apoptosis-inducing drugs

Apoptosis is a natural process through which cells with DNA too damaged to repair – such as cancer cells – can be forced to die. Many anti-cancer treatments (including radiation and chemo) cause cell changes that eventually lead to apoptosis. But targeted drugs in this group are different, because they are aimed specifically at the cell substances that control cell survival and death.

## The future of targeted therapies

As more is learned about the molecular biology of cancer, researchers will have more targets for their new drugs. Along with more monoclonal antibodies and small signaling pathway inhibitors, researchers are developing new classes of molecules such as antisense oligodeoxynucleotides and small interfering RNA (siRNA). Research is being done to develop targeted drugs that are aimed at proteins produced by specific gene mutations in cancer cells, too.

Researchers are looking for gene mutations that cause some patients to respond better to certain drugs.

## Hyperlinks

1. [www.cancer.org/cancer/types/colon-rectal-cancer.html](http://www.cancer.org/cancer/types/colon-rectal-cancer.html)
2. [www.cancer.org/cancer/types/kidney-cancer.html](http://www.cancer.org/cancer/types/kidney-cancer.html)
3. [www.cancer.org/cancer/types/lung-cancer.html](http://www.cancer.org/cancer/types/lung-cancer.html)

## References

American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention and Screening. Accessed at [www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA\\_2009.pdf](http://www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_2009.pdf) on June 8, 2012.

American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO's Annual Report on Progress Against Cancer. Accessed at [www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2010.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2010.pdf) on June 8, 2012.

American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO's Annual



Report on Progress Against Cancer. Accessed at [www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2011.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2011.pdf) on June 8, 2012.

American Society of Clinical Oncology. Progress & Timeline. Accessed at [www.cancerprogress.net/timeline/major-milestones-against-cancer](http://www.cancerprogress.net/timeline/major-milestones-against-cancer) on June 12, 2014.

CureToday. Timeline: Milestones in Cancer Treatment. Accessed at [www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article\\_id/631](http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/631) on June 7, 2012.

Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. *N Engl J Med*. 2012;366(23):2207-2214.

Last Revised: June 12, 2014

---

## Advancement of Cancer Survivorship

Only a few decades ago, the prognosis (outlook) for people facing cancer was not nearly as favorable as it is today. During the 1970s, about 1 of 2 people diagnosed with cancer survived at least 5 years. Now, more than 2 of 3 survive that long. Today there are more than 14 million cancer survivors in the United States alone.

Because more people are surviving cancer, more attention is focused on the quality of life and long-term outcomes of these cancer survivors. Behavioral researchers are working to learn more about the problems survivors face. Some of these problems are medical, such as permanent side effects of treatment, the possibility of second cancers caused by treatment, and the need for long-term treatment and medical follow-up. Other problems are emotional or social challenges, like getting health insurance, discrimination by employers, relationship changes that may result from life-threatening illness, or learning to live with the possibility of cancer coming back.

Cancer was once a word that people were afraid to speak in public, and people rarely admitted to being a cancer survivor. Now, many celebrities and national leaders very openly discuss and share their cancer experiences. The view that cancer cannot be cured and the fears that have historically been attached to the disease are slowly changing.

## References

American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention and Screening. Accessed at [www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA\\_2009.pdf](http://www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_2009.pdf) on June 8, 2012.

American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO's Annual Report on Progress Against Cancer. Accessed at [www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2010.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2010.pdf) on June 8, 2012.

American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO's Annual Report on Progress Against Cancer. Accessed at [www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA\\_2011.pdf](http://www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2011.pdf) on June 8, 2012.

American Society of Clinical Oncology. Progress & Timeline. Accessed at [www.cancerprogress.net/timeline/major-milestones-against-cancer](http://www.cancerprogress.net/timeline/major-milestones-against-cancer) on June 12, 2014.

CureToday. Timeline: Milestones in Cancer Treatment. Accessed at [www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article\\_id/631](http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/631) on June 7, 2012.

Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. *N Engl J Med*. 2012;366(23):2207-2214.

Last Revised: June 12, 2014

## Written by

The American Cancer Society medical and editorial content team  
(<https://www.cancer.org/cancer/acs-medical-content-and-news-staff.html>)

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

American Cancer Society medical information is copyrighted material. For reprint

requests, please see our Content Usage Policy ([www.cancer.org/about-us/policies/content-usage.html](http://www.cancer.org/about-us/policies/content-usage.html)).

**cancer.org | 1.800.227.2345**